Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300781 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
A Phase 2 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00300781 is a Phase 2 study that has completed, run by Puma Biotechnology. The registered enrollment target is 136 participants.
The verdict
NCT00300781, a Phase 2 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Interventions
- DRUG neratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2006-08-04 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300781
The ClinicalTrials.gov registry entry for NCT00300781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which neratinib is the first listed.
NCT00300781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300781 about?
NCT00300781 is a clinical study titled "Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer". The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
What is the current status of trial NCT00300781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2006-08-04. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT00300781?
The interventions under investigation include: neratinib (DRUG).
Who is sponsoring clinical trial NCT00300781?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.